METASTATIC NON-SMALL CELL LUNG CANCER
Clinical trials for METASTATIC NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for METASTATIC NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New lung cancer combo extends survival in phase 3 trial
Disease control CompletedThis phase 3 study tested a new combination of two immunotherapy drugs (pembrolizumab and vibostolimab) plus chemotherapy against the standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has spread. The trial included 739 p…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 12:11 UTC
-
New drug combo shows promise against lung cancer brain metastases
Disease control CompletedThis study tested two drugs, amivantamab and lazertinib, in 43 adults with a specific type of lung cancer (EGFR-mutant) that had spread to the brain and was getting worse despite previous treatments. The goal was to see if the combination could shrink or control brain tumors. Bot…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 12:08 UTC
-
Double-Drug attack on lung cancer shows promise in early trial
Disease control CompletedThis early-phase study tested the safety of combining two targeted drugs, dacomitinib and osimertinib, in 22 people with a specific type of advanced lung cancer (EGFR mutant). The goal was to find the highest safe dose and see how well the combination shrinks tumors. Participants…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 12:08 UTC
-
New approach uses targeted therapy to control metastatic lung cancer
Disease control CompletedThis study looked at whether a targeted treatment called local ablative therapy (LAT) can help control metastatic non-small cell lung cancer (NSCLC) when a blood test shows rising levels of cancer DNA (minimal residual disease or MRD). 37 participants received LAT to all visible …
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Blood test may predict lung cancer treatment success early
Knowledge-focused CompletedThis study looked at 100 people with advanced lung cancer to see if tracking tumor DNA in their blood could show early whether their treatment was working. Researchers measured changes in DNA levels after three weeks of therapy. The goal was to find a faster way to tell if a trea…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: NA • Sponsor: Centre Hospitalier Departemental Vendee • Aim: Knowledge-focused
Last updated May 22, 2026 14:03 UTC
-
Could your muscles predict cancer treatment success?
Knowledge-focused CompletedThis study looked at whether muscle loss (sarcopenia) and a blood test score (CRP-TyG index) can help predict how well immunotherapy works in people with advanced lung cancer. Researchers reviewed medical records of 115 adults treated at one hospital. They measured muscle on CT s…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated May 22, 2026 13:50 UTC